Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder

NCT00191698 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
November 30, 2007
Enrollment
226 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder, oppositional defiant disorder